Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-90
SponsorMassachusetts General Hospital
About this trial
This is a randomized, multicenter, double-blind, single administration study to investigate the efficacy and safety of 2 dosing regimens of Purified Cortrophin® Gel in the treatment of an acute gouty arthritis flare.
The study consists of three periods: an optional pre-screening period, a double-blind treatment period, and a 7-day follow-up period.
The treatment period is double-blind, and the patients will be randomized to treatment with 40 U Purified Cortrophin® Gel or 80 U Purified Cortrophin® Gel in a 1:1 ratio. Purified Cortrophin® Gel will be administered once (either subcutaneously or intramuscularly) on the first visit (Day 0; Visit 1) and surveyed after 24 hours (Day 1), 48 hours (Day 2), and 72 hours (Day 3; Visit 2) as well as on Day 7.
Eligibility criteria
Qualifiers
Signed informed consent to participate in this study
Male and female patients, aged 18-85 years
Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative
Onset of current acute gout flare within 5 days prior to study entry
Disqualifiers
Patients with scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, ocular herpes simplex, recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)), history of or the presence of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, uncontrolled diabetes type 1 or 2, or sensitivity to proteins derived from porcine sources.
Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
Rheumatoid arthritis, evidence or suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
Polyarticular gouty arthritis involving more than 4 joints.
Trial design
Treatments tested in this trial
- Purified Cortophin Gel, 40 U
- Purified Cortophin Gel 80 U
Treatment groups
150 Participants
are divided into 2 treatment groupsLocations
1Mass General Hospital02114, BostonMassachusetts, United States
Sponsors and collaborators
Massachusetts General Hospital
Lead sponsor
ANI Pharmaceuticals
Collaborator
Source ClinicalTrials.gov